Integral Molecular Partners with China’s Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics

On November 19, 2020 JOINN Laboratories, China’s leading preclinical contract research organization (CRO), reported that it has partnered with Integral Molecular to provide researchers in China with rapid antibody specificity testing against the entire human membrane proteome using Integral Molecular’s Membrane Proteome Array (MPA) technology (Press release, Integral Molecular, NOV 19, 2020, View Source [SID1234571450]). The ability to select lead candidates with high specificity will reduce safety liabilities prior to clinical development of therapeutic antibodies and CAR-T cancer treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Off-target binding of antibodies can result in severe or life-threatening adverse events, especially when antibody binding is used to direct cell killing, as with CAR-T cell therapeutics. Specificity testing using Integral Molecular’s MPA is now routinely included in investigational new drug (IND) applications submitted to regulatory agencies.

"At JOINN, we provide preclinical research services for most of the CAR-T cell therapeutics being developed in China," said Mr. Leon (Jingliang) Gu, EMT & VP of JOINN Laboratories. "We understand the possible consequences of misdirected cell killing and why MPA data represents a valuable component of preclinical packages submitted to the U.S. FDA and the National Medical Products Administration (NMPA) in China."

The MPA antibody specificity profiling service was developed by Integral Molecular as a comprehensive approach to detect binding of antibodies, cells, and other biologics to membrane protein targets for early de-risking of drug development. The MPA is the largest library of human membrane proteins, covering 94% of the membrane proteome and includes nearly all G protein-coupled receptors (GPCRs), ion channels, and transporters expressed in live cells.